Deerfield Management Company, L.P. (Series C) Pulmonx Corp Transaction History

Deerfield Management Company, L.P. (Series C)

$5.38 Billion
Q3 2024

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$5.77 - $9.82 $157,232 - $267,595	27,250 Added 134.31%	47,539 $301,000
Q1 2024 May 15, 2024	BUY	$8.71 - $14.65 $176,717 - $297,233	20,289 New	20,289 $188,000
Q3 2023 Nov 14, 2023	SELL	$9.88 - $14.0 $457,710 - $648,578	-46,327 Reduced 4.35%	1,017,958 $10.5 Million
Q2 2023 Aug 14, 2023	SELL	$10.78 - $13.65 $14.4 Million - $18.3 Million	-1,338,419 Reduced 55.7%	1,064,285 $14 Million
Q1 2023 May 15, 2023	BUY	$7.49 - $12.54 $18 Million - $30.1 Million	2,402,704 New	2,402,704 $26.9 Million
Q3 2022 Nov 14, 2022	BUY	$15.35 - $23.99 $3.91 Million - $6.12 Million	255,000 Added 7.36%	3,720,901 $62 Million
Q2 2022 Aug 15, 2022	SELL	$14.0 - $27.95 $3.21 Million - $6.41 Million	-229,440 Reduced 6.21%	3,465,901 $51 Million
Q1 2022 May 16, 2022	BUY	$21.13 - $35.65 $28.1 Million - $47.4 Million	1,328,474 Added 56.13%	3,695,341 $91.7 Million
Q4 2021 Feb 14, 2022	BUY	$29.72 - $45.1 $10 Million - $15.2 Million	336,980 Added 16.6%	2,366,867 $75.9 Million
Q3 2021 Nov 15, 2021	BUY	$35.98 - $44.48 $8.24 Million - $10.2 Million	229,000 Added 12.72%	2,029,887 $73 Million
Q2 2021 Aug 16, 2021	BUY	$37.61 - $48.0 $32.5 Million - $41.5 Million	863,855 Added 92.19%	1,800,887 $79.5 Million
Q1 2021 May 17, 2021	BUY	$44.0 - $67.54 $20.8 Million - $32 Million	473,521 Added 102.16%	937,032 $42.9 Million
Q4 2020 Feb 16, 2021	BUY	$39.31 - $69.02 $18.2 Million - $32 Million	463,511 New	463,511 $32 Million

Others Institutions Holding LUNG

# of Institutions

123

Shares Held

31M

Call Options Held

300

Put Options Held

204K

View Full List

About Pulmonx Corp

Ticker LUNG
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 37,268,400
Market Cap $236M
Description
Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a ...

More about LUNG

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deerfield Management Company, L.P. (Series C), based on Form 13F filings with the SEC.

News

Stay updated on Deerfield Management Company, L.P. (Series C) with notifications on news.

Account